Text Size:AAA

VEGF Targeted Therapy

Targeted Therapy
What is Targeted Therapy
Targeted Therapy: Targets
Targeted Therapy for Cancer
- Targeted Therapy for Kidney Cancer
- Targeted Therapy for Liver Cancer
- Colorectal Cancer Targeted Therapy
- What is Targeted Therapy for Cancer
- Targeted Therapy for Leukemia
- Targeted Therapy for Pancreatic Cancer
- Prostate Cancer Targeted Therapy
- Targeted Therapy for Ovarian Cancer
- Melanoma Targeted Therapy
- Targeted Therapy for Lung Cancer
- Targeted Therapy for Breast Cancer
EGFR Targeted Therapy
- EGFR Targeted Therapy for Breast Cancer
- EGFR Targeted Therapy for Colorectal Cancer
- EGFR Targeted Therapy for Head and Neck Cancer
- EGFR Targeted Therapy for Non-Small-Cell Lung Cancer
- EGFR Targeted Therapy for Ovarian Cancer
- EGFR Targeted Therapy for Pancreatic Cancer
HER2 Targeted Therapy
- HER2 Targeted Therapy for Breast Cancer
- HER2 Targeted Therapy for Colorectal Cancer
- Her2 targeted therapy for Ovarian cancer
VEGF Targeted Therapy
- VEGF Targeted Therapy for Breast Cancer
- VEGF Targeted Therapy for Lung Cancer
- VEGF Targeted Therapy for Prostate Cancer
- VEGF Targeted Therapy for Colorectal Cancer
BRAF Targeted Therapy
- BRAF Targeted Therapy for Melanoma
- BRAF Targeted Therapy for Lung Cancer
ALK Targeted Therapy
- ALK Targeted Therapy for Lung Cancer
- ALK Targeted Therapy for Anaplastic Large Cell Lymphoma
Immune Checkpoint Targeted Therapy
Targeted Therapy Drugs
- Targeted Therapy Drugs: Elotuzumab
- Targeted Therapy Drugs: Necitumumab
- Targeted Therapy Drugs: Daratumumab
- Targeted Therapy Drugs: Ramucirumab
- Targeted Therapy Drugs: Trastuzumab
- Targeted Therapy Drugs: Vemurafenib
- Targeted Therapy Drugs: Crizotinib
- The Differences between Chemotherapy and Targeted Therapy
Side Effects of Targeted Therapy
Oral Targeted Therapy
Targeted Therapy Resistance
How does Targeted Therapy Work
Immunotherapy
Cancer Immunotherapy
Immune checkpoint

VEGF Targeted Therapy: Introduction

Angiogenesis, the generation of new blood vessels, is an essential physiological process that can be dysregulated in various pathological conditions, including cancer. The vascular endothelial growth factor (VEGF) pathway is considered the most important and is a well-characterized contributor to angiogenesis. VEGF-A and other members of the VEGF family such as placental growth factor (PlGF) are upregulated in pathological conditions. VEGF-A, the first VEGF characterized, has served as a paradigm for the development of antiangiogenesis as a therapeutic strategy.

VEGF Targeted Therapy for Breast Cancer

Till now, the research of anti-VEGF on breast cancer has not yet succeeded except for the three initial trials.The US Food and Drug Administration approved ramucirumab for use in gastric cancer, where it (albeit modestly) improves both PFS and overall survival. However, VEGF-based therapy for breast cancer has gone through failures and failures.Since ramucirumab, like bevacizumab and sunitunib, target essentially the same process (VEGF-driven angiogenesis) in the same disease, its failure is perhaps unsurprising, just like what has happened in bevacizumab and sunitunib.

VEGF Targeted Therapy for Lung Cancer

Given that angiogenesis is an established hallmark of progressively detrimental tumors, including Lung cancer, inhibiting proangiogenic factors represents a potential avenue for therapeutic development. While the role of VEGF in angiogenesis is well-established, it is also known that additional signaling molecules and pathways contribute to aberrant blood vessel formation. Notably, some studies postulate that inhibiting VEGF and its receptors (VEGFRs) in early treatment settings may be beneficial, but that prolonged exposure to VEGF/VEGFR inhibitors may allow tumor cells to utilize alternative mechanisms to find oxygen and nutrients to sustain their growth.

VEGF Targeted Therapy for Prostate Cancer

Traditionally, androgen ablation has been the main treatment for the prevention of metastases from prostate cancer. As prostate cancer cells are initially dependant on androgens, suppressing the levels of testosterone and dihydrotestosterone decreases the growth rate of prostate cancer cells. However, after this initial response these cells can become castrate-resistant and develop a more aggressive phenotype, with increased VEGF expression and proliferative potential.
Due to the multifaceted effect VEGF has on tumour angiogenesis and tumour cell proliferation, antiangiogenic therapies targeting the VEGF pathways have shown promising early clinical application and are being investigated in clinical trials. These anti-VEGF therapies consist of VEGF-neutralizing antibodies and tyrosine kinase receptor inhibitors.

VEGF Targeted Therapy for Colorectal Cancer

Bevacizumab is a monoclonal antibody that binds and neutralizes vascular endothelial growth factor (VEGF)-A, a key player in the angiogenesis pathway. Despite benefits of bevacizumab in cancer therapy, it is clear that the VEGF pathway is complex, involving multiple isoforms, receptors, and alternative ligands such as VEGF-B, and placental growth factor, which could enable escape from VEGF-A-targeted angiogenesis inhibition. Recently developed therapies have targeted other ligands in the VEGF pathway (eg, aflibercept, known as ziv-aflibercept in the United States), VEGF receptors (eg, ramucirumab), and their tyrosine kinase signaling (ie, tyrosine kinase inhibitors) for Colorectal Cancer

請注意:所有產品都是“僅用於科研,而不能用於診斷或治療用途”